| 证券代码：300406 证券简称：九强生物 | 公告编号：2025-105 | | --- | --- | | 债券代码：123150 债券简称：九强转债 | | 北京九强生物技术股份有限公司 关于非独立董事辞职暨选举职工代表董事 及补选董事会专门委员会委员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、非独立董事辞职的情况 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到公司 非独立董事刘希先生的书面辞职报告，刘希先生因公司治理结构调整申请辞 去公司非独立董事、董事会战略委员会及薪酬与考核委员会委员职务。刘希 先生原定任期至公司第五届董事会届满之日，即自 2023 年 9 月 22 日至 2026 年 9 月 21 日止。刘希先生辞去公司非独立董事职务后，未导致公司董事会 成员人数低于法定最低人数，根据《中华人民共和国公司法》（以下简称"《公 司法》"）和《公司章程》等有关规定，其书面辞职报告自送达公司之日起 生效。 刘希先生辞职后，将继续在公司担任其他职务。截至本公告披露之日， 刘希先生持有公司股份 67,013,676 股，本次 ...

| 证券代码：300406 | 证券简称：九强生物 公告编号：2025-104 | | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | 北京九强生物技术股份有限公司 第五届董事会第二十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 北京九强生物技术股份有限公司(以下简称"公司")，于 2025 年 11 月 14 日在北京市海淀区花园东路 15 号旷怡大厦 5 层公司会议室召开了第五届 董事会第二十二次会议（以下简称"本次会议"）。经全体董事同意豁免会 议通知时间要求，本次会议采用现场会议方式召开。本次会议由公司董事长 邹左军主持，副董事长王永利、董事刘希、罗爱平、孙小林、王小亚、陈永 宏、杨建平、叶军出席了会议。公司高级管理人员列席了本次会议。 经审议，董事会同意对第五届董事会专门委员会委员予以补选，补选后 各委员会组成情况如下： 1、战略委员会：邹左军先生（召集人）、王永利先生、刘希先生、罗 爱平先生、杨建平先生； 2、审计委员会：陈永宏先生（召集人）、叶军先生、孙小林先生； 3、提 ...

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 | | | 北京九强生物技术股份有限公司 2025 年第二次临时股东大会决议公告 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议召开情况 （1）会议召开时间： 现场会议时间：2025 年 11 月 14 日（星期五）14:00 网络投票时间：2025 年 11 月 14 日（星期五） 其中：通过深圳证券交易所系统进行网络投票的具体时间为：2025 年 11 月 14 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 11 月 14 日 9:15 至 15:00 的任意时间。 （2）现场会议召开地点：公司会议室（北京市海淀区花园东路 15 号旷怡 大厦五层） （3）会议方式：本次股东大会采取现场投票与网络投票相结合的方式 （4）会议召集人：北京九强生物技术股份有限公司董事会 （5）会议主持人：董事长邹左军先生 会议的召集、召开程序符合有关法 ...

关于北京九强生物技术股份有限公司 2025年第二次临时股东大会 之 法律意见书 联慧意见（2025）字第【349】号 第一部分 前 言 致：北京九强生物技术股份有限公司 北京联慧律师事务所(以下简称"本所")接受贵公司委托，指派吴姝霖律师、 秦雪婷律师出席并见证公司2025年第二次临时股东大会(以下简称"本次股东大 会")，并依据《中华人民共和国公司法》(以下简称"《公司法》")、《中华 人民共和国证券法》(以下简称"《证券法》")、《上市公司股东会规则》(以 下简称"《股东会规则》")以及《北京九强生物技术股份有限公司章程》(以下 简称"《公司章程》")等有关规定，就本次股东大会的召集、召开程序、出席 现场会议人员的资格、召集人资格、会议表决程序及表决结果等事项出具本法律 意见书。为出具本法律意见书，本所律师审查了公司本次股东大会的有关文件和 材料。本所律师得到公司如下保证，即其已提供了本所律师认为出具本法律意见 书所必需的材料，所提供的原始材料、副本、复印件等材料、口头证言均符合真 实、准确、完整的要求，有关副本、复印件材料与正本原始材料一致。 在本法律意见书中，本所律师仅对本次股东大会的召集、召开程序、 ...

Group 1 - Company plans to repurchase shares worth between 50 million to 100 million yuan at a price not exceeding 14.00 yuan per share to reduce registered capital [1] - Company is engaged in investment operations, environmental engineering EPC, water treatment equipment production and sales, and water environment design consulting [1] Group 2 - Company announced a change in its joint venture investment project to a "100,000 tons/year waste rubber green low-carbon recycling preparation of carbon-based new materials project" with a total investment of 88 million yuan for the first phase [2][3] Group 3 - Company received an administrative regulatory measure decision from the Beijing Securities Regulatory Commission due to the failure to timely disclose the judicial freeze of shares [4] - The controlling shareholder's shares were frozen, accounting for 13.9% of the total share capital [4] Group 4 - Company is in the product development stage for its embodied intelligent robot business, which has not yet achieved mass production or revenue generation [5][6] Group 5 - Shareholders plan to reduce their holdings by up to 2.98% of the company's total shares through various trading methods [7][8] - Company specializes in the research, design, manufacturing, and sales of material handling equipment [9] Group 6 - Shareholders plan to reduce their holdings by up to 3% of the company's total shares [10][11] Group 7 - Shareholders plan to reduce their holdings by up to 1% of the company's total shares [12][18] Group 8 - Company announced the receipt of a property with an estimated value of 133 million yuan, which is expected to increase pre-tax profits by approximately 130 million yuan for the 2025 fiscal year [17][18] Group 9 - Company announced that its main product, phosphorus trichloride, is primarily used in the production of water treatment agents [19] - The company is facing risks related to the administrative approval process for a project that is behind schedule [19] Group 10 - Controlling shareholders plan to reduce their holdings by up to 3.66% of the company's total shares [20][21] Group 11 - Company signed a strategic framework agreement with a robotics company to collaborate on applications in intelligent manufacturing [22] Group 12 - Company plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [23] Group 13 - Controlling shareholder plans to transfer 5% of the company's shares as part of a cash acquisition arrangement [24] Group 14 - Company announced a change in control with a new controlling party following a share transfer agreement [25] Group 15 - Company plans to transfer 60% of its subsidiary's equity at a base price of 1.6756 million yuan, which is expected to reduce net profit by approximately 26.4 million yuan for the 2025 fiscal year [26] Group 16 - Major shareholder plans to provide a loan of up to 1.666 billion yuan to the company for debt repayment purposes [27]

Core Insights - On November 11, several A-share listed companies disclosed their share repurchase and reduction plans, indicating varying levels of confidence among shareholders in the market [1] Summary of Share Repurchase - Energy National plans to repurchase shares worth between 50 million to 100 million yuan [2] - Yuyuan shares intends to repurchase shares valued at 200 million to 300 million yuan [2] - Hot景生物 aims to repurchase shares worth between 100 million to 200 million yuan [2] Summary of Share Reduction - Yue Wannianqing's shareholders plan to reduce their holdings [2] - Jiuqiang Bio's shareholders intend to reduce no more than 0.38% of their shares [2] - Ningbo Fangzheng's major shareholders and actual controllers plan to reduce their holdings [2] - Suobao Protein's shareholders plan to collectively reduce no more than 3% of the company's shares [2] - Hetai Machinery's shareholder Haitai Jinghua plans to reduce no more than 2.98% of shares [2] - Yonghui Supermarket's private equity fund plans to reduce no more than 1% of shares [2] - Jiaojian shares' directors and executives plan to reduce their holdings [2] - Hongtong Gas's shareholder Tian Hui plans to reduce no more than 3% of shares [2] - Wentai Technology's major shareholders have cumulatively reduced 12.44 million shares recently [2] - Zhangzhou Beibei's directors and executives plan to collectively reduce no more than 0.0743% of shares [2] - Zhonggu Logistics' shareholder Gu Yang Investment plans to reduce no more than 3% of shares [2] - *ST Huawang's shareholder Wu Qun plans to reduce no more than 0.76% of shares [2]

Core Viewpoint - Zhou Xiaoyan, a natural person shareholder of Jiukang Bio (300406.SZ), plans to reduce her shareholding in the company by up to 2.2142 million shares within three months after the announcement, which represents 0.38% of the total share capital and voting shares [1] Summary by Relevant Sections - Shareholding Details - Zhou Xiaoyan holds 30.7696 million shares, accounting for 5.25% of the total share capital and 5.28% of the voting shares [1] - Reduction Plan - The planned reduction will occur through centralized bidding and/or block trading methods [1] - The maximum number of shares to be reduced is 2.2142 million, which is 0.38% of the total share capital and voting shares [1]

Core Viewpoint - Zhou Xiaoyan, a natural person shareholder of Jiukang Bio (300406.SZ), plans to reduce her shareholding in the company by up to 2.2142 million shares within three months after the announcement, representing 0.38% of the total share capital and voting shares [1] Summary by Relevant Sections - Shareholding Details - Zhou Xiaoyan holds 30.7696 million shares, accounting for 5.25% of the total share capital and 5.28% of the voting shares [1] - Reduction Plan - The planned reduction will occur through centralized bidding and/or block trading methods [1] - The maximum number of shares to be reduced is 2.2142 million, which is 0.38% of the total share capital and voting shares [1]

Core Viewpoint - The company announced that a major shareholder, Zhou Xiaoyan, plans to reduce their stake in the company by up to 2.2142 million shares, representing 0.38% of the total share capital, due to personal funding needs [1] Summary by Relevant Sections - **Shareholder Reduction Plan** - Zhou Xiaoyan, a natural person shareholder holding more than 5% of the company's shares, intends to reduce their holdings through centralized bidding and/or block trading [1] - The reduction is planned to occur within three months after the announcement, starting 15 trading days from the disclosure date [1] - The selling price will be determined based on the market price at the time of the reduction, indicating uncertainty in the implementation of this plan [1]

Group 1 - The core point of the news is that Zhou Xiaoyan, a natural person shareholder of Jiukang Biotechnology, plans to reduce her shareholding by up to 2.21 million shares, which represents 0.38% of the company's total share capital and voting shares [1][2] - Jiukang Biotechnology's revenue composition for the year 2024 is projected to be 100% from the healthcare sector [1] Group 2 - As of the report, Jiukang Biotechnology has a market capitalization of 8.2 billion yuan [2]